|
Jun 25
|
Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia
|
|
Jun 18
|
Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing Across 20+ Sites for Major Australian Waste Operator, Accelerating APAC Expansion
|
|
Jun 18
|
EXCLUSIVE: Intelligent Bio's Fingerprint Drug Testing Gains Momentum With New Australian Rollout
|
|
Jun 17
|
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Harry Simeonidis, President and CEO of Intelligent Bio Solutions Inc.
|
|
May 27
|
IBN Coverage: Intelligent Bio Solutions (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows
|
|
May 22
|
IBN Coverage: Intelligent Bio Solutions (NASDAQ: INBS) to Showcase Fingerprint Drug Testing at RISE25 Conference
|
|
May 22
|
Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing
|
|
May 15
|
IBN Coverage: Intelligent Bio Solutions (NASDAQ: INBS) Surpasses 450 Accounts as Fingerprint Drug Testing Expands Globally
|
|
May 15
|
Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing
|
|
May 13
|
IBN Coverage: Intelligent Bio Solutions (NASDAQ: INBS) Grows Revenue, Cuts Losses in Fiscal Q3 as Cartridge Sales Drive Margins
|
|
May 13
|
Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements
|
|
May 13
|
EXCLUSIVE: Intelligent Bio Solutions Q3 Gross Profit Jumps By 91%
|
|
Mar 11
|
Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th
|
|
Feb 21
|
Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares of Common Stock
|
|
Feb 20
|
Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock
|
|
Feb 19
|
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock
|
|
Feb 15
|
Intelligent Bio Solutions Second Quarter 2025 Earnings: US$0.50 loss per share (vs US$2.07 loss in 2Q 2024)
|
|
Feb 13
|
Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements
|
|
Feb 11
|
Intelligent Bio releases shareholder letter on 2024 growth, 2025 strategy
|
|
Feb 10
|
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy
|